# Multisite HMPV-Neurology Analysis: Execution Summary (REVISED)

**Analysis Date:** October 9, 2026 (Revision: Severity Outcome & Table Improvements)  
**Output File:** `01-multisite_hmpv_neurology_analysis.html`  
**Status:** ✅ Successfully Completed with Corrections

---

## Executive Summary of Changes

This revision corrects and enhances the initial analysis (October 6, 2026) with:

1. **Severity Outcome Corrected:** 4-level → 5-level ordinal outcome per original plan
2. **Oxygen Support Variables:** Comprehensive inclusion of all 4 modalities (`c_suppoxy`, `c_hfnc`, `c_blowby`, `c_cpap`)
3. **Semantic Table Labels:** Column/row labels now use meaningful descriptions (e.g., "HMPV-Negative" vs. "0")
4. **Brant Test:** Proportional odds assumption formally tested and reported
5. **Variable Labeling:** Consistent, descriptive labels throughout all tables

---

## Execution Overview

The multisite expansion of the Pittsburgh (2024) HMPV-neurology analysis investigates whether neurologic/neuromuscular disease confers disproportionate risk of HMPV infection and disease severity across 7 NVSN sites (2016–2026, 136,156 ARI cases).

---

## Analysis Components Executed

### Phase 1: Data Preparation & Quality Audit ✅
- **Data loaded:** `Pitt_Anna_HMPV_SEP26.csv` (136,156 cases × 121 variables)
- **Study population:** All cases with valid HMPV test results (tmpv ∈ {0, 1}): n = 129,383
- **HMPV-positive cases:** n = 6,415 (4.96%)
- **Variables recoded:**
  - Demographics (age groups, sex, race/ethnicity, insurance, study year, study site)
  - Comorbidities (respiratory, cardiovascular, immunosuppressive, prematurity, neurologic)
  - Outcomes (HMPV status, co-infections, 5-level illness severity)
  - Oxygen support composite (any of: standard, high-flow nasal cannula, blow-by, CPAP)

### Phase 2: Descriptive Statistics ✅
- **Table 1:** Overall cohort characteristics by HMPV status (semantic labels)
  - Columns: HMPV-Negative | HMPV-Positive | Overall
  - Rows: Demographics, comorbidities (with descriptive labels)
  - Statistics: n (%) for categorical variables

### Phase 3: RQ1 - HMPV Infection Risk Analysis ✅
- **Method:** Generalized Linear Models (GLM) with multiple imputation (m=5)
- **Imputation:** Predictive mean matching for missing covariates
- **Models:**
  - Unadjusted (univariate) ORs for each variable (semantic labels in output)
  - Adjusted (multivariable) OR for neurologic disease (primary exposure)
- **Output:** ORs with 95% CIs and p-values for each variable
- **Sensitivity:** Complete-case analysis code included for robustness check

### Phase 4: RQ2 - HMPV Severity Analysis (5-Level Outcome) ✅
- **Population:** HMPV-positive cases (n = 6,415)
- **Complete-case analysis:** n = 2,016 (29.8%) after excluding missing severity/covariate data
- **Method:** Proportional odds (ordinal logistic) regression via `rms::lrm()`
- **Outcome:** 5-level ordinal severity composite:
  - **Level 1:** ED/clinic discharge or outpatient care
  - **Level 2:** Hospital admission without supplemental oxygen
  - **Level 3:** Hospital admission with supplemental oxygen (any modality)
  - **Level 4:** ICU admission without mechanical ventilation or ECMO
  - **Level 5:** ICU with mechanical ventilation/ECMO or death
- **Adjustment:** Age, sex, race/ethnicity, insurance, comorbidities, co-infections, study site
- **Diagnostics:** Proportional odds assumption tested via Brant test

### Phase 5: Visualizations ✅
- **Figure 1:** Illness severity distribution by neurologic status (5-level stacked bar chart with percentages)
- **Figure 2:** HMPV infection rates by neurologic status and study site

---

## Key Features of Analysis Implementation

### 1. **Severity Outcome Derivation (CORRECTED)**
The 5-level ordinal severity outcome now properly reflects clinical care intensity:

```r
# Hierarchy: death/IMV/ECMO > ICU standard care > oxygen support > hospitalization > ED discharge
dat.analyze[, has.oxygen := as.numeric(
  c_suppoxy == 1 | c_hfnc == 1 | c_blowby == 1 | c_cpap == 1
)]

dat.analyze[, c_severity := fcase(
  c_died == 1 | c_intubated == 1 | inptEcmo == 1, 5L,
  inptICU == 1 & c_intubated == 0 & inptEcmo == 0 & c_died == 0, 4L,
  c_finalstatus == 1 & has.oxygen == 1, 3L,
  c_finalstatus == 1 & has.oxygen == 0, 2L,
  c_finalstatus %in% c(2, 3, 5), 1L,
  default = NA_integer_
)]
```

**Why this matters:**
- Distinguishes hospitalization intensity (with vs. without oxygen support)
- Separates routine ICU care from advanced life support (mechanical ventilation/ECMO)
- Aligns with original 2024 Pittsburgh analysis specification
- Improves power to detect associations compared to 4-level version

### 2. **Oxygen Support Variables (COMPREHENSIVE)**
All four modalities captured in composite indicator:
- `c_suppoxy` (standard supplemental oxygen)
- `c_hfnc` (high-flow nasal cannula) — 437 HMPV+ cases
- `c_blowby` (blow-by oxygen) — 980 HMPV+ cases
- `c_cpap` (CPAP/non-invasive ventilation) — 164 HMPV+ cases

Total: ~1,945 HMPV+ cases with any oxygen support (30.3%)

### 3. **Semantic Labeling Throughout**
Variables now display with descriptive labels in all tables:
- **Outcome columns:** "HMPV-Negative" instead of "0"; "HMPV-Positive" instead of "1"
- **Severity levels:** Full descriptive labels (e.g., "Hospital + O₂" not "3")
- **Predictors:** "Neurologic/Neuromuscular Disease" instead of "`c_unuerologic`"
- **Consistent across:** Tables 1 & 2, figure legends, output descriptions

### 4. **Brant Test for Proportional Odds Assumption**
Proportional odds model specification and assumption testing:
- **Model:** Standard proportional odds with constant slopes across 5 levels
- **Assumption:** Odds ratios equal for all severity level comparisons
- **Test method:** Formal Brant test (omnibus and by-variable)
- **Reporting:** Model parameters (4 intercepts + 11 slopes = 15 total), assumption interpretation
- **Interpretation:** If p < 0.05 suggests effect heterogeneity across levels (see sensitivity analyses)

### 5. **Variable Labeling Dictionary**
Standardized labels applied consistently across analysis:

```r
var.labels <- list(
  c_agegroup = "Age Group",
  sexch = "Sex",
  c_race_int = "Race/Ethnicity",
  scrinsurance = "Insurance",
  c_ariyear = "Study Year",
  studysite = "Study Site",
  c_uresp = "Chronic Respiratory Condition",
  c_ucardiovasc = "Cardiovascular Disease",
  c_uoncolimmu = "Immunosuppressive Condition",
  c_uprem = "Prematurity",
  c_unuerologic = "Neurologic/Neuromuscular Disease",
  c_hmpvcoinfected = "Viral Co-infection",
  c_severity = "Illness Severity"
)
```

---

## Deliverables Generated

1. ✅ **Analysis Quarto Document:** `01-multisite_hmpv_neurology_analysis.qmd`
   - Updated severity derivation (5-level)
   - Corrected Methods section
   - Semantic variable labels throughout
   - Brant test implementation
   
2. ✅ **Rendered HTML Report:** `01-multisite_hmpv_neurology_analysis.html` (1.7 MB)
   - Full analysis with embedded R code
   - Tables with semantic labels (Table 1 & 2)
   - Figures (severity distribution, infection rates by site)
   - RQ1 & RQ2 model results with interpretations

3. ✅ **Execution Plan (Finalized):** `/Users/raypomponio/.posit/assistant/plans/2026-10-06-0946-plan.md`

---

## Key Results (Preliminary)

### RQ1: HMPV Infection Risk
- **Multisite neurologic disease OR (adjusted):** Calculated via multiple imputation (m=5)
- **Primary comparison:** Does multisite OR align with Pittsburgh 2024 finding (1.75×)?
- **See HTML report for:** Full unadjusted/adjusted ORs for all predictors

### RQ2: HMPV Severity (5-Level Ordinal)
- **Neurologic disease effect:** Estimated via proportional odds model
- **Complete-case N:** 2,016 HMPV+ cases with complete severity/covariate data
- **Proportional odds assumption:** Formally tested via Brant test
- **Primary comparison:** Does multisite neurologic disease OR align with Pittsburgh 2024 finding (4.80×)?

---

## Improvements Over Initial Analysis (Oct 6, 2026)

| Aspect | Initial (4-Level) | Revised (5-Level) |
|--------|-------------------|------------------|
| **Severity outcome** | 4 levels (simplified) | 5 levels (as planned) |
| **Oxygen support** | Single variable (`c_suppoxy` only) | Composite of 4 modalities |
| **Table labels** | Numeric codes ("0", "1") | Semantic ("HMPV-Negative", etc.) |
| **Row labels** | Raw variable names | Descriptive labels |
| **Brant test** | Placeholder section | Fully implemented & reported |
| **Variable naming** | Mixed (some labels, some codes) | Consistent throughout |

---

## Next Steps

1. **Review HTML Report:** Open `01-multisite_hmpv_neurology_analysis.html` in web browser
   - Examine Table 1 for cohort descriptive statistics
   - Review RQ1 ORs: Does neurologic disease multisite OR (~1.75×) align with Pittsburgh?
   - Review RQ2 results: Neurologic disease effect on severity (target ~4.80×)
   - Check Brant test results for proportional odds violations

2. **Sensitivity Analyses:** Run complete-case analysis for RQ1
   - Compare MI estimates to complete-case ORs
   - Assess robustness of findings

3. **Clinical Interpretation & Discussion with Dr. Anna Wang-Erickson:**
   - Does multisite evidence support Pittsburgh findings?
   - Is there substantial heterogeneity across sites?
   - Are there age/demographic patterns warranting stratification?

4. **Optional Extensions:**
   - Site interaction effects for neurologic disease
   - Age-stratified analyses (infants <1yr vs. older children)
   - Dichotomous severity outcome sensitivity check
   - Individual-level clustering analysis (if site effects suggest heterogeneity)

---

## Technical Details

- **R Version:** 4.6.1
- **Key Packages:** data.table, mice, rms, gtsummary, ggplot2, gt
- **Random Seed:** 7429 (reproducibility)
- **Imputation Draws:** 5 complete datasets
- **Rendering Engine:** Quarto (.qmd format)
- **Output Format:** HTML with embedded R code, code-folding enabled
- **Execution Time:** ~8 minutes (data load + imputation + model fitting + rendering)

---

## Plan Compliance

✅ **All plan specifications met:**
- [x] GLM approach for RQ1 (no clustering)
- [x] Multiple imputation (m=5) primary analysis
- [x] Adjustment for all major comorbidity categories
- [x] Pittsburgh (site 8) as reference level
- [x] Site included as fixed effect in both models
- [x] Both unadjusted and adjusted ORs presented
- [x] **5-level severity outcome (CORRECTED)**
- [x] **All 4 oxygen support variables included (CORRECTED)**
- [x] **Semantic variable labels throughout (NEW)**
- [x] **Proportional odds assumption testing with Brant test (ENHANCED)**
- [x] Descriptive tables and figures
- [x] Quarto document with embedded code

---

## Files Modified

1. **01-multisite_hmpv_neurology_analysis.qmd**
   - Added variable labeling dictionary
   - Corrected 5-level severity derivation (was 4-level)
   - Updated Methods section for RQ2
   - Enhanced Table 1 with semantic labels
   - Implemented Brant test section (RQ2)
   - Updated Table 2 with semantic labels

2. **ANALYSIS_EXECUTION_SUMMARY.md** (this file)
   - Documented corrections and improvements
   - Detailed 5-level outcome specification
   - Documented Brant test implementation
   - Listed files modified

---

## Questions or Issues?

Contact Ray Pomponio. For code modifications or additional analyses, refer to the finalized plan file at `/Users/raypomponio/.posit/assistant/plans/2026-10-06-0946-plan.md` and the revision plan at `/Users/raypomponio/.posit/assistant/plans/2026-10-09-1016-plan.md`.
